- Conditions
- Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
- Interventions
- LY3561774, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- Waterbury, Connecticut • Oxon Hill, Maryland • Fall River, Massachusetts + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 45
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Mixed Dyslipidemia
- Interventions
- ARO-ANG3, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Huntington Park, California • Hialeah, Florida • Miami, Florida + 10 more
- Conditions
- Severe Hypertriglyceridemia, Mixed Dyslipidaemia
- Interventions
- Gemcabene, Placebo
- Drug
- Lead sponsor
- NeuroBo Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 48
- States / cities
- Fort Payne, Alabama • Tucson, Arizona • Beverly Hills, California + 41 more
- Conditions
- Dyslipidaemia
- Interventions
- TAP311 capsules, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Miramar, Florida
- Conditions
- Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
- Interventions
- Evolocumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more
- Conditions
- Primary Hypercholesterolemia, Mixed Dyslipidemia
- Interventions
- Evolocumab Pre-filled Syringe, Evolocumab AI/pen
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 21
- States / cities
- Encino, California • Thousand Oaks, California • Ventura, California + 17 more
- Conditions
- Type II Diabetes Mellitus, Mixed Dyslipidemia
- Interventions
- fenofibrate 160 mg and placebo, simvastatin 20 mg and placebo, fenofibrate 160 mg and simvastatin 20 mg
- Drug
- Lead sponsor
- Intermountain Health Care, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 2
- States / cities
- Ogden, Utah • Salt Lake City, Utah
- Conditions
- Cardiovascular Diseases, Hyperlipidemias
- Interventions
- Lipid Challenge, Glucose Challenge, Mixed Meal Challenge
- Dietary Supplement
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Dyslipidemia
- Interventions
- LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 38
- States / cities
- Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more
- Conditions
- Hypercholesterolemia, Mixed Dyslipidemia
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11,991 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Mixed Dyslipidemia
- Interventions
- BW-00112
- Drug
- Lead sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 14
- States / cities
- Daphne, Alabama • Mobile, Alabama • Boca Raton, Florida + 10 more
- Conditions
- Hyperlipidemia and Mixed Dyslipidemia
- Interventions
- Evolocumab, Standard of Care
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 3,681 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more
- Conditions
- HIV Infections, Hyperlipidemia, Exercise
- Interventions
- l-carnitine
- Dietary Supplement
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Hyperlipidemia, Mixed Hyperlipidemia, Dyslipidemia
- Interventions
- Niacin Extended Release/Lovastatin
- Drug
- Lead sponsor
- In His Image
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Tulsa, Oklahoma
- Conditions
- Hypercholesterolemia, Mixed Dyslipidemia, Type 2 Diabetes
- Interventions
- Evolocumab, Placebo to Evolocumab
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 46
- States / cities
- Tuscumbia, Alabama • Phoenix, Arizona • Lomita, California + 39 more
- Conditions
- Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias
- Interventions
- Vupanorsen, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 59
- States / cities
- Gilbert, Arizona • Little Rock, Arkansas • Lincoln, California + 35 more
- Conditions
- Hypertension, Hyperglycemia, Dyslipidemia, Metabolic Syndrome, Obesity &Amp; Overweight, Diabetes, Hyperlipidemia, Emergency Medicine
- Interventions
- Composite intervention to address MetS
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Dyslipidemia
- Interventions
- PRC-4016, Placebo, Statins
- Drug
- Lead sponsor
- Pronova BioPharma
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 29
- States / cities
- Huntsville, Alabama • Muscle Shoals, Alabama • Beverly Hills, California + 24 more
- Conditions
- Diabetes, Hyperlipidemia, Mixed Dyslipidemia
- Interventions
- Evolocumab, Atorvastatin, Placebo
- Biological · Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 11
- States / cities
- Miami, Florida • Atlanta, Georgia • Indianapolis, Indiana + 8 more
- Conditions
- Hyperlipidemia, Dyslipidemia
- Interventions
- NK-104-CR, Livalo® IR, Placebo (for NK-104-CR), Placebo (for Livalo® IR)
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 69
- States / cities
- Foley, Alabama • Huntsville, Alabama • Montgomery, Alabama + 66 more
- Conditions
- PFAS, Environmental Exposures, Occupational Exposure to Chemicals, Military Exposure, Burn Pit Exposure, Forever Chemicals, Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia, Hyperlipidemia (E.G., Hypercholesterolemia)
- Interventions
- Colesevelam, Placebo
- Drug
- Lead sponsor
- University of Rhode Island
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Louisville, Kentucky • Augusta, Maine
- Conditions
- Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia, Mixed Dyslipidemia
- Interventions
- ABT-335, placebo, atorvastatin, ezetimibe
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 543 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 118
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Hueytown, Alabama + 107 more
- Conditions
- Mixed Dyslipidemia, Coronary Heart Disease, Dyslipidemia
- Interventions
- ABT-335, Atorvastatin, Placebo
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- North Chicago, Illinois
- Conditions
- Mixed Dyslipidemia
- Interventions
- ABT-335, rosuvastatin calcium, simvastatin, atorvastatin calcium
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Abbott Park, Illinois